RDC Stock Analysis: Redcare Pharmacy | XETRA
Pharmaceutical Retailers | XETRA, Germany | Market Cap: 1.231m EUR | 12M Return: -28.5% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 9.25M
Rev. Trend: 98.4%
Qual. Beats: 1
Warnings
Tailwinds
Seasonality 9.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Redcare Pharmacy NV is a pure-play online pharmacy headquartered in Sevenum, the Netherlands, operating across seven European markets: the Netherlands, Germany, Italy, Belgium, Switzerland, Austria, and France. Founded in 2001 and previously known as Shop Apotheke Europe N.V., the company rebranded to Redcare Pharmacy NV in June 2023.
The companys product portfolio covers three main categories: prescription medications, over-the-counter (OTC) pharmaceuticals, and adjacent consumer health categories including beauty, personal care, and food supplements. This mix blends regulated pharmacy products with higher-margin consumer staples.
As a digitally native operator in the GICS Drug Retail sub-industry, Redcare competes with traditional brick-and-mortar pharmacy chains by serving customers through an e-commerce platform rather than physical storefronts. The European online pharmacy segment has expanded as consumers and regulators have increasingly accepted digital channels for both prescription fulfillment and everyday health and personal care purchases.
- German e-prescription rollout accelerates prescription revenue growth
- Active customer base expansion in France drives top-line growth
- Competitive pressure from DocMorris and Amazon Pharmacy pressures margins
| Net Income: -37.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.08 > 0.02 and ΔFCF/TA -7.16 > 1.0 |
| NWC/Revenue: 6.64% < 20% (prev 9.04%; Δ -2.39% < -1%) |
| CFO/TA 0.01 > 3% & CFO 10.8m > Net Income -37.4m |
| Net Debt (297.2m) to EBITDA (70.8m): 4.20 < 3 |
| Current Ratio: 1.54 > 1.5 & < 3 |
| Outstanding Shares: last quarter (20.1m) vs 12m ago 0.03% < -2% |
| Gross Margin: 20.57% > 18% (prev 22.36%; Δ -1.79% > 0.5%) |
| Asset Turnover: 279.4% > 50% (prev 247.4%; Δ 31.96% > 0%) |
| Interest Coverage Ratio: -0.23 > 6 (EBIT TTM -5.25m / Interest Expense TTM 22.9m) |
| A: 0.17 (Total Current Assets 579.3m - Total Current Liabilities 375.1m) / Total Assets 1.18b |
| B: -0.26 (Retained Earnings -305.7m / Total Assets 1.18b) |
| C: -0.00 (EBIT TTM -5.25m / Avg Total Assets 1.10b) |
| D: 0.63 (Book Value of Equity 450.2m / Total Liabilities 710.1m) |
| Altman-Z'' = 0.92 = BB |
| DSRI: 1.11 (Receivables 156.4m/116.2m, Revenue 3.07b/2.53b) |
| GMI: 1.09 (GM 22.36% / 20.57%) |
| AQI: 0.83 (AQ_t 0.34 / AQ_t-1 0.41) |
| SGI: 1.22 (Revenue 3.07b / 2.53b) |
| TATA: -0.04 (NI -37.4m - CFO 10.8m) / TA 1.18b) |
| Beneish M = -2.81 (Cap -4..+1) = A |
As of July 14, 2026, the stock is trading at EUR 65.90 with a total of 95,877 shares traded. Over the past week, the price has changed by -5.79%, over one month by +15.01%, over three months by +64.75% and over the past year by -28.52%.
Current recommended Stop Loss: 57.40 (which is 12.9% or 2.2 ATR below the current price).
Redcare Pharmacy has no consensus analysts rating.
P/E Forward = 625.0
P/S = 0.4005
P/B = 3.0243
Revenue TTM = 3.07b EUR
EBIT TTM = -5.25m EUR
EBITDA TTM = 70.8m EUR
Long Term Debt = 261.9m EUR (from longTermDebt, last fiscal year)
Short Term Debt = 23.0m EUR (from shortTermDebt, last quarter)
Debt = 432.2m EUR (from shortLongTermDebtTotal, last quarter) + Leases 77.4m
Net Debt = 297.2m EUR (calculated: Debt 432.2m - CCE 135.0m)
Enterprise Value = 1.53b EUR (1.23b + Debt 432.2m - CCE 135.0m)
Interest Coverage Ratio = -0.23 (Ebit TTM -5.25m / Interest Expense TTM 22.9m)
EV/FCF = -17.03x (Enterprise Value 1.53b / FCF TTM -89.7m)
FCF Yield = -5.87% (FCF TTM -89.7m / Enterprise Value 1.53b)
FCF Margin = -2.92% (FCF TTM -89.7m / Revenue TTM 3.07b)
Net Margin = -1.22% (Net Income TTM -37.4m / Revenue TTM 3.07b)
Gross Margin = 20.57% ((Revenue TTM 3.07b - Cost of Revenue TTM 2.44b) / Revenue TTM)
Gross Margin QoQ = 18.95% (prev 18.05%)
Tobins Q-Ratio = 1.30 (Enterprise Value 1.53b / Total Assets 1.18b)
Interest Expense / Debt = 5.31% (Interest Expense 22.9m / Debt 432.2m)
Taxrate = 25.0% (non-US conservative default 25%)
NOPAT = -3.94m (EBIT -5.25m * (1 - 25.00%)) [loss with tax shield]
Current Ratio = 1.54 (Total Current Assets 579.3m / Total Current Liabilities 375.1m)
Debt / Equity = 0.96 (Debt 432.2m / totalStockholderEquity, last quarter 450.2m)
Debt / EBITDA = 4.20 (Net Debt 297.2m / EBITDA 70.8m)
Debt / FCF = -3.31 (negative FCF - burning cash) (Net Debt 297.2m / FCF TTM -89.7m)
Total Stockholder Equity = 480.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -3.40% (Net Income -37.4m / Total Assets 1.18b)
RoE = -7.79% (Net Income TTM -37.4m / Total Stockholder Equity 480.1m)
RoCE = -0.71% (EBIT -5.25m / Capital Employed (Equity 480.1m + L.T.Debt 261.9m))
RoIC = -0.57% (negative operating profit) (NOPAT -3.94m / Invested Capital 691.3m)
WACC = 7.34% (E(1.23b)/V(1.66b) * Re(8.52%) + D(432.2m)/V(1.66b) * Rd(5.31%) * (1-Tc(0.25)))
Discount Rate = 8.52% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 78.77 | Cagr: 0.50%
[DCF] Fair Price = unknown (Cash Flow -89.7m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: N/A | # QB: 0
Revenue Correlation: 98.41 | Revenue CAGR: 31.06% | SUE: 4.0 | # QB: 1
EPS current Quarter (2026-06-30): EPS=-0.30 | Chg30d=+11.00% | Revisions=+25% | Analysts=1
EPS current Year (2026-12-31): EPS=-0.89 | Chg30d=+10.29% | Revisions=+40% | GrowthEPS=+36.4% | GrowthRev=+15.7%
EPS next Year (2027-12-31): EPS=0.99 | Chg30d=+47.37% | Revisions=+57% | GrowthEPS=+211.1% | GrowthRev=+11.5%
[Analyst] Revisions Ratio: +70% (up=7, down=0)